

Bartter syndrome

Template:Infobox - genetic disease '*Bartter syndrome is an AR hereditary tubulopathy with a combination of impaired water and electrolyte metabolism. The syndrome arises as a consequence of a complex disorder of tubular transport and excretion of ions.*

Etiology

Diseases are caused by **abnormalities** of three different **transport systems**: $\text{Na}^+/\text{K}^+/\text{2Cl}^-$ cotransporter, potassium channel and chloride channel.

Pathogenesis

$\text{Na}^+/\text{K}^+/\text{2Cl}^-$ -cotransporter defect (NKCC2, an ATP-independent ion channel)^[1] in the ascending part of the loop of Henle of the nephron leads to insufficient absorption of sodium, and its reduced level in the *macula densa* will increase the activity of the RAAS, which leads to an increase in the level of aldosterone and to **secondary hyperaldosteronism** with all clinical symptoms (blood pressure is normal).

Clinical picture

The main symptoms include:

- hypokalemia (significant muscle weakness)
- alkalosis
- hypercalciuria
- polyuria
- hyperrenin hyperaldosteronism
- growth disorders.

According to the type of defective transport system, we recognize 6 types of Bartter syndrome. ^[2]

Type I - $\text{Na}^+/\text{K}^+/\text{2Cl}^-$ -cotransporter defect (NKCC2, gene "SLC12A"); manifests already in infancy, mostly in children born prematurely to mothers with polyhydramnios^[3].

Type II – ATP-dependent apical potassium channel defect (ROMK1, gene *KCNJ1*); phenotypically it is the same as type I.

Type III - basolateral chloride channel defect (ClC-Kb, gene *CLCNKB*); hypomagnesemia is observed in 30% of patients (types I and II do not have it)^[3].

Type IVa' – β -subunit defect of the basolateral chloride channel (Barttin, gene *BSND*); characteristic **trias**: Bartter's syndrome, renal insufficiency, hearing impairment^[3].

Type IVb - combined dysfunction of two chloride channels ClC-Ka and ClC-Kb (genes "CLCNKA" and "CLCNKB"), prenatal manifestation, polyhydramnios

Type V - transient form (defect in the *MAGED2* gene), polyhydramnios, excessive salt loss with secondary metabolic alkalosis, disappears spontaneously in the first months of life

Therapy

The therapy is only **symptomatic**, its basis is diet adjustment and ion substitution^[2].

Prognosis

The prognosis of the disease is uncertain, some patients develop mental retardation or kidney failure.

Links

References

1. CASTROP, Hayo – SCHIESSL, Ina Maria. Physiology and pathophysiology of the renal Na-K-2Cl cotransporter (NKCC2). *Am J Physiol Renal Physiol* [online]. 2014, vol. 307, no. 9, p. F991-F1002, Available from <<https://www.ncbi.nlm.nih.gov/pubmed/25186299>>. ISSN 1522-1466.
2. ZIEG, Jacob – DOLEŽEL, Zdeněk. Bartter and Gitelman syndrome. *Čas Lék Czech* [online]. 2022, vol. 161, no. 3-4, p. 131-134, Available from <<https://www.prolekare.cz/casopisy/casopis-lekaru-ceskych/2022-3-4-1/bartteruv-a-gitelmanuv-syndrom-131752>>. ISSN 0008-7335.
3. HERALD, Gerd, et al. *Innere Medizin*. 1. edition. 2016. 1000 pp. ISBN 9783981466058.

References

- CHILD, P., et al. *Internal medicine*. 2. edition. Prague : Galen, 2007. ISBN 978-80-7262-496-6.
- KLENER, P, et al. *Internal medicine*. 3. edition. Prague : Galen, 2006. ISBN 80-7262-430-X.